Clinical Trials Browser

Recruiting × Ovarian Cancer Recurrent × Clear all

NCT06791460 2025-03-18

Pegylated Liposomal Doxorubicin Plus Adebrelimab With or Without Mirabegron in Relapsed Ovarian Cancer

Phase 2/3 Recruiting

Ovarian Cancer Recurrent

NCT06660511 2024-10-28

Exploratory Study on the Safety and Efficacy of Disitamab Vedotin in Combination with Anlotinib Hydrochloride for the Treatment of HER-2-expressing Recurrent Platinum-resistant Ovarian Cancer.

Phase EARLY_PHASE1 Recruiting

Ovarian Cancer Recurrent